We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Dendrite International, Inc. (NASDAQ: DRTE) announced today that, at a special meeting held in Bedminster,?NJ, Dendrite?s shareholders approved its acquisition by French...
NEW YORK, May 2 /PRNewswire-FirstCall/ Standard & Poor's will make the following changes to the S&P SmallCap 600 index: * Texas Roadhouse Inc. (NASDAQ:TXRH) will replace Global Imaging...
Dendrite International, Inc. (NASDAQ: DRTE) today announced that its proposed acquisition by French company, Cegedim SA (?Cegedim?), has cleared U.S. antitrust review, but...
Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, today announced that it plans to release its fourth quarter earnings after...
Dendrite International, Inc. (NASDAQ: DRTE) announced today three contract signings in Japan to expand its leadership position for sales force effectiveness solutions in the...
Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, today announced that the Company plans to provide its revenue and E.P.S...
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry solutions, today announced that the Company and its chairman and chief executive...
Pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended as of October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE) today announced that stock options covering...
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry solutions, today announced a strategic relationship with Microsoft Corp. (NASDAQ: MSFT...
Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, today announced that the company has signed a three-year field support...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions